Synthetic biology and precision medicine in blood and gynaecological cancers
Prof José Feio speaks to ecancer at the 2019 Biosimilars Educational Advanced Masterclass for Pharmacists (P-BEAM) in Zurich about the implementation of biosimilars in a hospital using centralised management systems.
He describes the success of this program and its applicability to other hospitals around the world.
Feio also outlines the positive impact this had on patient care and outcomes.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
If you would like to learn more about biosimilar medicines, please visit our free e-learning modules here.
Synthetic biology and precision medicine in blood and gynaecological cancers
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours